Form 8-K - Current report:
SEC Accession No. 0001193125-25-011456
Filing Date
2025-01-23
Accepted
2025-01-23 16:10:58
Documents
15
Period of Report
2025-01-23
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d832952d8k.htm   iXBRL 8-K 27351
2 EX-99.1 d832952dex991.htm EX-99.1 8894
6 GRAPHIC g832952page5.jpg GRAPHIC 5818
  Complete submission text file 0001193125-25-011456.txt   171701

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vinc-20250123.xsd EX-101.SCH 2839
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vinc-20250123_lab.xml EX-101.LAB 17979
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vinc-20250123_pre.xml EX-101.PRE 11251
17 EXTRACTED XBRL INSTANCE DOCUMENT d832952d8k_htm.xml XML 3631
Mailing Address 260 SHERIDAN AVENUE SUITE 400 PALO ALTO CA 94306
Business Address 260 SHERIDAN AVENUE SUITE 400 PALO ALTO CA 94306 650-800-6676
Vincerx Pharma, Inc. (Filer) CIK: 0001796129 (see all company filings)

EIN.: 833197402 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39244 | Film No.: 25550209
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)